Human CMV infection induces 5-lipoxygenase expression and leukotriene B4 production in vascular smooth muscle cells

被引:54
作者
Qiu, Hong [2 ]
Straat, Klas [1 ]
Rahbar, Afsar [1 ]
Wan, Min [2 ]
Soederberg-Naucler, Cecilia [1 ]
Haeggstroem, Jesper Z. [2 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, Dept Med, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 2, SE-17176 Stockholm, Sweden
关键词
D O I
10.1084/jem.20070201
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Leukotrienes (LTs) are powerful proinflammatory lipid mediators that may play a central role in cardiovascular diseases, including arteriosclerosis, myocardial infarction, and stroke. Owing to restricted expression of 5-lipoxygenase (5-LO), the enzyme required for their synthesis, LTs are almost exclusively produced by myeloid cells. Here, we report that human cytomegalovirus ( HCMV) infection of human vascular smooth muscle cells (SMCs) increases 5-LO mRNA levels by up to 170-fold in a dose- and time-dependent manner. Infected cells expressed 5-LO protein, as shown by immunohistochemistry, enabling them to synthesize bioactive LTB4. HCMV-infected vascular SMCs expressing 5-LO protein were readily detected in tissue samples from CMV-infected patients with inflammatory bowel disease or AIDS. Thus, pathogen-induced LT production in HCMV-infected tissues may contribute to local inflammation, consistent with the ability of HCMV to control cellular and immunological functions. HCMV-induced LT biosynthesis in SMCs offers a molecular mechanism to explain HCMV-induced pathogenesis in inflammatory diseases.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 30 条
[1]   Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice [J].
Aiello, RJ ;
Bourassa, PA ;
Lindsey, S ;
Weng, WF ;
Freeman, A ;
Showell, HJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (03) :443-449
[2]  
Cottone M, 2001, AM J GASTROENTEROL, V96, P773, DOI 10.1111/j.1572-0241.2001.03620.x
[3]   Mechanisms of leukocyte recruitment to atherosclerotic lesions: future prospects [J].
Eriksson, EE .
CURRENT OPINION IN LIPIDOLOGY, 2004, 15 (05) :553-558
[4]   Release of anti-HIV mediators after administration of leukotriene B4 to humans [J].
Flamand, L ;
Borgeat, P ;
Lalonde, R ;
Gosselin, J .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (11) :2001-2009
[5]   Leukotriene modifiers as potential therapeutics for cardiovascular disease [J].
Funk, CD .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (08) :664-672
[6]   CYTOKINES AND ARACHIDONIC METABOLITES PRODUCED DURING HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-INFECTED MACROPHAGE-ASTROGLIA INTERACTIONS - IMPLICATIONS FOR THE NEUROPATHOGENESIS OF HIV DISEASE [J].
GENIS, P ;
JETT, M ;
BERNTON, EW ;
BOYLE, T ;
GELBARD, HA ;
DZENKO, K ;
KEANE, RW ;
RESNICK, L ;
MIZRACHI, Y ;
VOLSKY, DJ ;
EPSTEIN, LG ;
GENDELMAN, HE .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (06) :1703-1718
[7]   Leukotriene B4 protects latently infected mice against murine cytomegalovirus reactivation following allogeneic transplantation [J].
Gosselin, J ;
Borgeat, P ;
Flamand, L .
JOURNAL OF IMMUNOLOGY, 2005, 174 (03) :1587-1593
[8]  
Gupta S, 2001, CANCER-AM CANCER SOC, V91, P737, DOI 10.1002/1097-0142(20010215)91:4<737::AID-CNCR1059>3.0.CO
[9]  
2-F
[10]  
HENDRIX MGR, 1990, AM J PATHOL, V136, P23